ORCHID BIOSCIENCES INC
10-Q, EX-27, 2000-11-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ORCHID BIOSCIENCES INC, 10-Q, 2000-11-14
Next: CALLISTO CAPITAL MANAGEMENT INC, 13F-HR, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2000, AND THE
RELATED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE NINE MONTHS
ENDED SEPTEMBER 30, 2000 AND 1999, AND THE NOTES THERETO FROM ITEM 1 OF
THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30,
2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
AND NOTES.
</LEGEND>
<MULTIPLIER>     1,000

<S>                             <C>                     <C>
<PERIOD-TYPE>                   9-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-1999
<PERIOD-START>                             JAN-01-2000             JAN-01-1999
<PERIOD-END>                               SEP-30-2000             SEP-30-1999
<CASH>                                          14,881                       0
<SECURITIES>                                    59,851                       0
<RECEIVABLES>                                    4,871                       0
<ALLOWANCES>                                       133                       0
<INVENTORY>                                      3,614                       0
<CURRENT-ASSETS>                                84,925                       0
<PP&E>                                          20,132                       0
<DEPRECIATION>                                  (3,329)                      0
<TOTAL-ASSETS>                                 147,953                       0
<CURRENT-LIABILITIES>                            7,713                       0
<BONDS>                                              0                       0
                                0                       0
                                          0                       0
<COMMON>                                            33                       0
<OTHER-SE>                                     136,873                       0
<TOTAL-LIABILITY-AND-EQUITY>                   147,953                       0
<SALES>                                         10,866                       0
<TOTAL-REVENUES>                                12,991                   1,246
<CGS>                                            8,264                       0
<TOTAL-COSTS>                                   50,436                  15,165
<OTHER-EXPENSES>                                    76                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                 279                     944
<INCOME-PRETAX>                                (34,533)                (14,723)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                            (34,533)                (14,723)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                   (34,533)                (14,723)
<EPS-BASIC>                                      (3.61)                 (20.20)
<EPS-DILUTED>                                    (3.61)                 (20.20)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission